Clinical Comprehensive Evaluation of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation Versus Budesonide and Formoterol Fumarate Powder for Inhalation in the Treatment of Bronchial Asthma in Children
Objective:To evaluate the clinical comprehensive value of salmeterol xinafoate and fluticasone propionate powder for inhalation versus budesonide and formoterol fumarate powder for inhalation in the treatment of bronchial asthma in children so as to provide reference for drug selection and clinical medication decision in hospital.Methods:Data of randomized controlled trials were retrieved from domestic and foreign literature databases to perform the efficacy and safety evaluation.Direct medical costs of children with bronchial asthma in a tertiary hospital were retrospectively analyzed and economic evaluation was performed.Innovation,suitability and accessibility evaluation were carried out through questionnaire investigation and collection of relevant drug procurement and sales data as well as package inserts.Results:A total of 326 articles were retrieved,and 3 articles were finally included,including a total of 298 patients,with 148 patients in the intervention group(salmeterol xinafoate and fluticasone propionate powder for inhalation)and 150 patients in the control group(budesonide and formoterol fumarate powder for inhalation).Meta-analysis showed that there was no statistically significant difference in the incidence of adverse reactions between salmeterol xinafoate and fluticasone propionate powder for inhalation and budesonide and formoterol fumarate powder for inhalation in the treatment of bronchial asthma in children[OR=1.03,95%CI(0.62,1.73),P=0.91].The response rate with salmeterol xinafoate and fluticasone propionate powder for inhalation was lower than that with budesonide and formoterol fumarate powder for inhalation[OR=0.49,95%CI(0.25,0.97),P=0.04].The results of economic evaluation showed that salmeterol xinafoate and fluticasone propionate powder for inhalation was not more economic as compared with budesonide and formoterol fumarate powder for inhalation in the treatment of bronchial asthma in children.A total of 52 questionnaires were collected,and the results showed that salmeterol xinafoate and fluticasone propionate powder for inhalation was not significantly more innovative,suitable and accessible as compared with budesonide and formoterol fumarate powder for inhalation.Conclusion:Salmeterol xinafoate and fluticasone propionate powder for inhalation has low clinical value in the treatment of bronchial asthma in children,has not been included in the Essential Drug List of China,and exhibits no clinical advantages.
salmeterol xinafoate and fluticasone propionate powder for inhalationbudesonide and formoterol fumarate powder for inhalationbronchial asthmachildrenclinical comprehensive evaluation
万方数据
维普
